A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1257

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Ixekizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company